Temozolomide-based Second-line Chemotherapy in Patients with Advanced Bronchopulmonary Neuroendocrine Tumours

#1298

Introduction: The management of advanced Bronchopulmonary Neuroendocrine Tumours (BP-NET) is not standardized. There are only few clinical studies of Temozolomide (TMZ) as monotherapy or in combination with other agents available for BP-NET.

Aim(s): To evaluate the efficacy and safety of TMZ-based chemotherapy (CTX) in a cohort of patients (pts) with pre-treated advanced BP-NET.

Materials and methods: Twenty-five pts who underwent treatment with TMZ-based CTX at our institution for BP-NET, excluding small cell lung cancer, between 2010 and 2015 were included. The RECIST 1.1 objective response rates (ORRs) and toxicity following NCI-CTCv4 criteria were retrospectively assessed.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Tabaksblat E, Ladekarl M,

Keywords: temozolomide, BP-NET, Ki-67 index,

To read the full abstract, please log into your ENETS Member account.